Shun Fu Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shun Fu Lee has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Jeff Healey
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
3 shared publications Shrikant I. Bangdiwala
Population Health Research Institute, McMaster University, Hamilton, Canada
3 shared publicationsHertzel C. Gerstein
Population Health Research Institute, McMaster University, Hamilton, Canada
2 shared publications- Hertzel C. Gerstein
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
2 shared publications Jessica Spence
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
2 shared publications- Juan Benezet-Mazuecos
Department of Cardiology, Hospital Universitario La Luz , Madrid
2 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 165, 108293
Internal pilot sample size re-estimation for the B-free trial: A case study of a cluster randomized crossover trial
- 27 March 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 165, 108293
Open AccessInternal pilot sample size re-estimation for the B-free trial: A case study of a cluster randomized crossover trial
- Open Access
- 8 August 2025
- Published by SAGE Publications in Clinical Trials
- Vol. 22 (6) , 687-694
Training the next generation of clinical trial biostatisticians
Background: There is a critical shortage of biostatistics expertise and targeted training programs in clinical trials across Canada. Methods: The Canadian Network for Statistical Training in Trials (CANSTAT), a pan-Canadian, multi-institutional training platform for biostatisticians in clinical trials, was developed to increase clinical trial biostatistics capacity in Canada. Results: CANSTAT’s training program integrates experiential learning through mentorship and placements at clinical trial sites, online workshops, and capacity-building meetings. The curriculum is designed to equip fellows with essential knowledge of clinical trials, technical skills, and practical experience necessary for their growth into professional trial biostatisticians, with several specific and measurable objectives set to achieve this goal. Educational materials, including CANSTAT competencies, reflective exercises, and individual development plans, are provided to monitor progress and ensure that fellows are meeting their academic and professional goals. Currently, CANSTAT has enrolled 19 fellows. Conclusion: CANSTAT has developed a training program that equips fellows with essential skills in clinical trial design, conduct and analysis, and interprofessional communication, preparing them to effectively lead biostatistical efforts in clinical trials. By training a new generation of clinical trial biostatisticians, CANSTAT is strengthening Canada’s clinical trial enterprise and improving health outcomes.
- 8 August 2025
- Published by SAGE Publications in Clinical Trials
- Vol. 22 (6) , 687-694
Open AccessTraining the next generation of clinical trial biostatisticians
Background: There is a critical shortage of biostatistics expertise and targeted training programs in clinical trials across Canada. Methods: The Canadian Network for Statistical Training in Trials (CANSTAT), a pan-Canadian, multi-institutional training platform for biostatisticians in clinical trials, was developed to increase clinical trial biostatistics capacity in Canada. Results: CANSTAT’s training program integrates experiential learning through mentorship and placements at clinical trial sites, online workshops, and capacity-building meetings. The curriculum is designed to equip fellows with essential knowledge of clinical trials, technical skills, and practical experience necessary for their growth into professional trial biostatisticians, with several specific and measurable objectives set to achieve this goal. Educational materials, including CANSTAT competencies, reflective exercises, and individual development plans, are provided to monitor progress and ensure that fellows are meeting their academic and professional goals. Currently, CANSTAT has enrolled 19 fellows. Conclusion: CANSTAT has developed a training program that equips fellows with essential skills in clinical trial design, conduct and analysis, and interprofessional communication, preparing them to effectively lead biostatistical efforts in clinical trials. By training a new generation of clinical trial biostatisticians, CANSTAT is strengthening Canada’s clinical trial enterprise and improving health outcomes.
- Open Access
- 9 June 2025
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 25 (1) , 1-12
Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials
In cardiovascular (CV) trials, analyzing the total number of events, rather than just time-to-first event, enhances understanding of participants' health. Adapting Cox models to account for between-subject heterogeneity in multiple events and understanding its impact plays crucial roles in total event analysis. This study compares effect sizes from first event and total event analyses in three cardiovascular trials: ORIGIN (N = 12,537, median follow-up of 6.2 years), COMPASS (N = 18,278, median follow-up of 1.8 years), TRANSCEND (N = 5,926, median follow-up of 1.1 years). It also examines the impact of heterogeneity, measured by the negative binomial overdispersion parameter. Treatment effects were assessed using the Cox model for first events and the negative binomial (NB), Andersen-Gill (AG), Prentice-Williams-Peterson (PWP), Wei-Lin-Weissfeld (WLW), and Lin-Wei-Yang-Ying (LWYY) models for total events. Hazard ratios (HRs) or risk ratios (RRs), 95% confidence intervals (CIs), and CI widths were reported. The risk ratio applies to negative binomial. The first composite was consisted of myocardial infarction (MI), stroke, cardiovascular death. Simulations assessed Type I error, power, and mean squared error across the different approaches. In ORIGIN, the incidence per 100 years increased from 2.9 to 3.8 for the first composite with a heterogeneity of 2.4. The HR or RR for the first composite was 1.03 (95% CI, 0.94–1.12, CI width = 0.18) using Cox, 1.01 (95% CI, 0.92–1.11, CI width = 0.19) for NB, 1.01 (95% CI, 0.94–1.09, CI width = 0.15) for AG, 1.02 (95% CI, 0.94–1.10, CI width = 0.16) for PWP total, 1.01 (95% CI, 0.94–1.09, CI width = 0.15) for PWP gap, 1.03 (95% CI, 0.94–1.12, CI width = 0.18) for WLW and 1.01 (95% CI, 0.92–1.11, CI width = 0.19) for LWYY. Similar trends were observed in other studies. Our simulation results showed that total event approaches had approximately 5% higher power than the Cox model, though power declined exponentially across all methods with increasing heterogeneity. Among the total event methods, AG, PWP gap, and LWYY demonstrated better power, with AG and LWYY also achieving the smallest mean squared error (MSE). High heterogeneity arises when a small number of patients experience a disproportionately large number of events. This effect is more pronounced when the overall event incidence is low and few patients experience any events. The effect size and CI width stayed consistent with low heterogeneity across different approaches. Power decreased with high heterogeneity. The AG and LWYY approaches slightly outperformed the other approaches. ORIGIN (NCT00069784), COMPASS (NCT01776424), TRANSCEND (NCT00153101).
- 9 June 2025
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 25 (1) , 1-12
Open AccessComparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials
In cardiovascular (CV) trials, analyzing the total number of events, rather than just time-to-first event, enhances understanding of participants' health. Adapting Cox models to account for between-subject heterogeneity in multiple events and understanding its impact plays crucial roles in total event analysis. This study compares effect sizes from first event and total event analyses in three cardiovascular trials: ORIGIN (N = 12,537, median follow-up of 6.2 years), COMPASS (N = 18,278, median follow-up of 1.8 years), TRANSCEND (N = 5,926, median follow-up of 1.1 years). It also examines the impact of heterogeneity, measured by the negative binomial overdispersion parameter. Treatment effects were assessed using the Cox model for first events and the negative binomial (NB), Andersen-Gill (AG), Prentice-Williams-Peterson (PWP), Wei-Lin-Weissfeld (WLW), and Lin-Wei-Yang-Ying (LWYY) models for total events. Hazard ratios (HRs) or risk ratios (RRs), 95% confidence intervals (CIs), and CI widths were reported. The risk ratio applies to negative binomial. The first composite was consisted of myocardial infarction (MI), stroke, cardiovascular death. Simulations assessed Type I error, power, and mean squared error across the different approaches. In ORIGIN, the incidence per 100 years increased from 2.9 to 3.8 for the first composite with a heterogeneity of 2.4. The HR or RR for the first composite was 1.03 (95% CI, 0.94–1.12, CI width = 0.18) using Cox, 1.01 (95% CI, 0.92–1.11, CI width = 0.19) for NB, 1.01 (95% CI, 0.94–1.09, CI width = 0.15) for AG, 1.02 (95% CI, 0.94–1.10, CI width = 0.16) for PWP total, 1.01 (95% CI, 0.94–1.09, CI width = 0.15) for PWP gap, 1.03 (95% CI, 0.94–1.12, CI width = 0.18) for WLW and 1.01 (95% CI, 0.92–1.11, CI width = 0.19) for LWYY. Similar trends were observed in other studies. Our simulation results showed that total event approaches had approximately 5% higher power than the Cox model, though power declined exponentially across all methods with increasing heterogeneity. Among the total event methods, AG, PWP gap, and LWYY demonstrated better power, with AG and LWYY also achieving the smallest mean squared error (MSE). High heterogeneity arises when a small number of patients experience a disproportionately large number of events. This effect is more pronounced when the overall event incidence is low and few patients experience any events. The effect size and CI width stayed consistent with low heterogeneity across different approaches. Power decreased with high heterogeneity. The AG and LWYY approaches slightly outperformed the other approaches. ORIGIN (NCT00069784), COMPASS (NCT01776424), TRANSCEND (NCT00153101).
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1747-1755
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial
BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population. METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA 2 DS 2 -VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect. RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted P interaction =0.1). The duration of the longest SCAF episode in the 6 months before enrollment was not associated with the risk of stroke or systemic embolism during follow-up (6 hours: 1.0%/patient-year [adjusted hazard ratio, 1.02 (95% CI, 0.63–1.66)]). SCAF duration did not modify the reduction in stroke or systemic embolism with apixaban ( P trend =0.1). CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01938248.
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1747-1755
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial
BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population. METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA 2 DS 2 -VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect. RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted P interaction =0.1). The duration of the longest SCAF episode in the 6 months before enrollment was not associated with the risk of stroke or systemic embolism during follow-up (6 hours: 1.0%/patient-year [adjusted hazard ratio, 1.02 (95% CI, 0.63–1.66)]). SCAF duration did not modify the reduction in stroke or systemic embolism with apixaban ( P trend =0.1). CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01938248.
- Open Access
- 2 October 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-10
Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches
The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) questionnaires are commonly used to measure global cognition in clinical trials. Because these scales are discrete and bounded with ceiling and floor effects and highly skewed, their analysis as continuous outcomes presents challenges. Normality assumptions of linear regression models are usually violated, which may result in failure to detect associations with variables of interest. Alternative approaches to analyzing the results of these cognitive batteries include transformations (standardization, square root, or log transformation) of the scores in the multivariate linear regression (MLR) model, the use of nonlinear beta-binomial regression (which is not dependent on the assumption of normality), or Tobit regression, which adds a latent variable to account for bounded data. We aim to empirically compare the model performance of all proposed approaches using four large randomized controlled trials (ORIGIN, TRANSCEND, COMPASS, and NAVIGATE-ESUS), and using as metrics the Akaike information criterion (AIC). We also compared the treatment effects for the methods that have the same unit of measure (i.e., untransformed MLR, beta-binomial, and Tobit). The beta-binomial consistently demonstrated superior model performance, with the lowest AIC values among nearly all the approaches considered, followed by the MLR with square root and log transformations across all four studies. Notably, in ORIGIN, a substantial AIC reduction was observed when comparing the untransformed MLR to the beta-binomial, whereas other studies had relatively small AIC reductions. The beta-binomial model also resulted in a significant treatment effect in ORIGIN, while the untransformed MLR and Tobit regression showed no significance. The other three studies had similar and insignificant treatment effects among the three approaches. When analyzing discrete and bounded outcomes, such as cognitive scores, as continuous variables, a beta-binomial regression model improves model performance, avoids spurious significance, and allows for a direct interpretation of the actual cognitive measure. ORIGIN (NCT00069784). Registered on October 1, 2003; TRANSCEND (NCT00153101). Registered on September 9, 2005; COMPASS (NCT01776424). Registered on January 24, 2013; NAVIGATE-ESUS (NCT02313909). Registered on December 8, 2014.
- 2 October 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-10
Open AccessImproving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches
The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) questionnaires are commonly used to measure global cognition in clinical trials. Because these scales are discrete and bounded with ceiling and floor effects and highly skewed, their analysis as continuous outcomes presents challenges. Normality assumptions of linear regression models are usually violated, which may result in failure to detect associations with variables of interest. Alternative approaches to analyzing the results of these cognitive batteries include transformations (standardization, square root, or log transformation) of the scores in the multivariate linear regression (MLR) model, the use of nonlinear beta-binomial regression (which is not dependent on the assumption of normality), or Tobit regression, which adds a latent variable to account for bounded data. We aim to empirically compare the model performance of all proposed approaches using four large randomized controlled trials (ORIGIN, TRANSCEND, COMPASS, and NAVIGATE-ESUS), and using as metrics the Akaike information criterion (AIC). We also compared the treatment effects for the methods that have the same unit of measure (i.e., untransformed MLR, beta-binomial, and Tobit). The beta-binomial consistently demonstrated superior model performance, with the lowest AIC values among nearly all the approaches considered, followed by the MLR with square root and log transformations across all four studies. Notably, in ORIGIN, a substantial AIC reduction was observed when comparing the untransformed MLR to the beta-binomial, whereas other studies had relatively small AIC reductions. The beta-binomial model also resulted in a significant treatment effect in ORIGIN, while the untransformed MLR and Tobit regression showed no significance. The other three studies had similar and insignificant treatment effects among the three approaches. When analyzing discrete and bounded outcomes, such as cognitive scores, as continuous variables, a beta-binomial regression model improves model performance, avoids spurious significance, and allows for a direct interpretation of the actual cognitive measure. ORIGIN (NCT00069784). Registered on October 1, 2003; TRANSCEND (NCT00153101). Registered on September 9, 2005; COMPASS (NCT01776424). Registered on January 24, 2013; NAVIGATE-ESUS (NCT02313909). Registered on December 8, 2014.
- Open Access
- 2 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (46) , 4902-4916
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death. In patients with vascular disease (NOAH-AFNET 6 56%, ARTESiA 46.0%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6 2.7%/patient-year, ARTESiA 2.3%/patient-year in both randomised groups). Meta-analysis found consistent results across both trials (I2heterogeneity=6%) with a trend for interaction with randomised therapy (pinteraction=0.08). Stroke/SE behaved similarly. Anticoagulation increased major bleeding in vascular disease patients (edoxaban 2.1%/patient-year, no anticoagulation 1.3%/patient-year; apixaban 1.7%/patient-year; no anticoagulation 1.1%/patient-year; incidence rate ratio 1.55 [1.10-2.20]) and without vascular disease (edoxaban 2.2%/patient-year; no anticoagulation 0.6%/patient-year; apixaban 1.4%/patient-year; no anticoagulation 1.1%/patient-year, incidence rate ratio 1.93 [0.72-5.20]). Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.
- 2 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (46) , 4902-4916
Open AccessAnticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death. In patients with vascular disease (NOAH-AFNET 6 56%, ARTESiA 46.0%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6 2.7%/patient-year, ARTESiA 2.3%/patient-year in both randomised groups). Meta-analysis found consistent results across both trials (I2heterogeneity=6%) with a trend for interaction with randomised therapy (pinteraction=0.08). Stroke/SE behaved similarly. Anticoagulation increased major bleeding in vascular disease patients (edoxaban 2.1%/patient-year, no anticoagulation 1.3%/patient-year; apixaban 1.7%/patient-year; no anticoagulation 1.1%/patient-year; incidence rate ratio 1.55 [1.10-2.20]) and without vascular disease (edoxaban 2.2%/patient-year; no anticoagulation 0.6%/patient-year; apixaban 1.4%/patient-year; no anticoagulation 1.1%/patient-year, incidence rate ratio 1.93 [0.72-5.20]). Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.
- Open Access
- 11 November 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 206, 111010
Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia
- 11 November 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 206, 111010
Open AccessSex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia
- Open Access
- 1 June 2020
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 22 (6) , 870-877
Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis
Data on patient characteristics, prevalence, and outcomes of atrial fibrillation (AF) patients without traditional risk factors, often labelled ‘lone AF’, are sparse. The RE-LY AF registry included 15 400 individuals who presented to emergency departments with AF in 47 countries. This analysis focused on patients without traditional risk factors, including age ≥60 years, hypertension, coronary artery disease, heart failure, left ventricular hypertrophy, congenital heart disease, pulmonary disease, valve heart disease, hyperthyroidism, and prior cardiac surgery. Patients without traditional risk factors were compared with age- and region-matched controls with traditional risk factors (1:3 fashion). In 796 (5%) patients, no traditional risk factors were present. However, 98% (779/796) had less-established or borderline risk factors, including borderline hypertension (130–140/80–90 mmHg; 47%), chronic kidney disease (eGFR < 60 mL/min; 57%), obesity (body mass index > 30; 19%), diabetes (5%), excessive alcohol intake (>14 units/week; 4%), and smoking (25%). Compared with patients with traditional risk factors (n = 2388), patients without traditional risk factors were more often men (74% vs. 59%, P < 0.001) had paroxysmal AF (55% vs. 37%, P < 0.001) and less AF persistence after 1 year (21% vs. 49%, P < 0.001). Furthermore, 1-year stroke occurrence rate (0.6% vs. 2.0%, P = 0.013) and heart failure hospitalizations (0.9% vs. 12.5%, P < 0.001) were lower. However, risk of AF-related re-hospitalization was similar (18% vs. 21%, P = 0.09). Almost all patients without traditionally defined AF risk factors have less-established or borderline risk factors. These patients have a favourable 1-year prognosis, but risk of AF-related re-hospitalization remains high. Greater emphasis should be placed on recognition and management of less-established or borderline risk factors.
- 1 June 2020
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 22 (6) , 870-877
Open AccessCharacteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis
Data on patient characteristics, prevalence, and outcomes of atrial fibrillation (AF) patients without traditional risk factors, often labelled ‘lone AF’, are sparse. The RE-LY AF registry included 15 400 individuals who presented to emergency departments with AF in 47 countries. This analysis focused on patients without traditional risk factors, including age ≥60 years, hypertension, coronary artery disease, heart failure, left ventricular hypertrophy, congenital heart disease, pulmonary disease, valve heart disease, hyperthyroidism, and prior cardiac surgery. Patients without traditional risk factors were compared with age- and region-matched controls with traditional risk factors (1:3 fashion). In 796 (5%) patients, no traditional risk factors were present. However, 98% (779/796) had less-established or borderline risk factors, including borderline hypertension (130–140/80–90 mmHg; 47%), chronic kidney disease (eGFR < 60 mL/min; 57%), obesity (body mass index > 30; 19%), diabetes (5%), excessive alcohol intake (>14 units/week; 4%), and smoking (25%). Compared with patients with traditional risk factors (n = 2388), patients without traditional risk factors were more often men (74% vs. 59%, P < 0.001) had paroxysmal AF (55% vs. 37%, P < 0.001) and less AF persistence after 1 year (21% vs. 49%, P < 0.001). Furthermore, 1-year stroke occurrence rate (0.6% vs. 2.0%, P = 0.013) and heart failure hospitalizations (0.9% vs. 12.5%, P < 0.001) were lower. However, risk of AF-related re-hospitalization was similar (18% vs. 21%, P = 0.09). Almost all patients without traditionally defined AF risk factors have less-established or borderline risk factors. These patients have a favourable 1-year prognosis, but risk of AF-related re-hospitalization remains high. Greater emphasis should be placed on recognition and management of less-established or borderline risk factors.